FrancophonIA/ELRC3.0 huggingface dataset:
English: • Pain and redness at the injection site
Estonian: • süstekoha valu ja punetus.
English: 10 x 1 dose 1 dose (0.5 ml)
Estonian: 10 x 1 annus 1 annus (0,5 ml)
English: ♦ Rare (less than 1 per 1000 but more than 1 per 10,000 doses of vaccine):
Estonian: ♦ Harv (vähem kui ühel 1000st, kuid rohkem kui ühel 10 000st annusest):
English: NAME OF THE MEDICINAL PRODUCT Daronrix, suspension for injection in multidose container Pandemic influenza vaccine (whole virion, inactivated, adjuvanted)
Estonian: RAVIMPREPARAADI NIMETUS Daronrix, süstesuspensioon mitmeannuselises konteineris Pandeemilise gripiviiruse vaktsiin (täisviirus, inaktiveeritud, adjuveeritud)
English: NAME OF THE MEDICINAL PRODUCT Daronrix, suspension for injection in pre-filled syringe Pandemic influenza vaccine (whole virion, inactivated, adjuvanted)
Estonian: RAVIMPREPARAADI NIMETUS Daronrix, süstesuspensioon eeltäidetud süstlas Pandeemilise gripiviiruse vaktsiin (täisviirus, inaktiveeritud, adjuveeritud)
English: Disodium phosphate dodecahydrate Potassium dihydrogen phosphate Potassium chloride Magnesium chloride hexahydrate Thiomersal
Estonian: Dinaatriumfosfaatdodekahüdraat Kaaliumdivesinikfosfaat Kaaliumkloriid
English: • Fits
Estonian: • tõmblused;
English: • Fatigue
Estonian: Ravimohutus
English: Adults from the age of 18 to 60 years will receive two injections of Daronrix, the first injection will be administered at an elected date, the second at least three weeks after the first injection.
Estonian: Esimene süst tehakse valitud päeval ja teine vähemalt kolm nädalat pärast esimest süsti.
English: Vasculitis with transient renal involvement.
Estonian: Vaskuliit koos mööduva neeru haaratusega.
English: BEFORE YOU RECEIVE DARONRIX
Estonian: MIDA ON VAJA TEADA ENNE DARONRIX´I KASUTAMIST
English: Suspension for injection Vial
Estonian: RAVIMI VÄLJASTAMISTINGIMUSED Retseptiravim
English: Therefore health care providers need to assess the benefits and potential risks of administering the vaccine in that population.
Estonian: Puuduvad andmed Daronrix´i kasutamise kohta alla 18-aastastel lastel, mistõttu peavad tervishoiutöötajad hindama vaktsiini manustamisest saadavat kasu ja potentsiaalseid riske selles populatsioonis.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING MONODOSE PRESENTATION
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED ÜHEANNUSELINE
English: Uncommon (≥1/1,000 to <1/100) Rare (≥1/10,000 to <1/1,000) Very rare (<1/10,000)
Estonian: Aeg-ajalt (≥1/1000 ja <1/100)
English: The patient takes one capsule one hour before starting each chemotherapy cycle.
Estonian: Patsient võtab ühe kapsli üks tund enne iga keemiaravi tsükli algust.
English: The full EPAR and risk management plan summary for Akynzeo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Akynzeo kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: One of the active substances, palonosetron, has been authorised on its own in the EU since 2005.
Estonian: Toimeaine palonosetroon on Euroopa Liidus eraldi heaks kiidetud alates 2005. aastast.
English: What measures are being taken to ensure the safe and effective use of Akynzeo?
Estonian: Mis meetmed võetakse, et tagada Akynzeo ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Akynzeo is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Akynzeo võimalikult ohutu kasutamine.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Akynzeo on 27 May 2015
Estonian: Euroopa Komisjon andis Akynzeo müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 27. mail
English: Akynzeo netupitant / palonosetron hydrochloride
Estonian: Akynzeo netupitant/palonosetroonvesinikkloriid
English: Other information about Akynzeo
Estonian: Muu teave Akynzeo kohta
English: The Committee therefore concluded that the medicine's benefits are greater than its risk and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas seetõttu, et ravimi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Why is Akynzeo approved?
Estonian: Miks Akynzeo heaks kiideti?
English: The most common side effects reported with Akynzeo are headache (seen in 3.6% of patients), constipation (3.0%) and fatigue (1.2%).
Estonian: Akynzeo kõige sagedamad kõrvalnähud on peavalu (esines 3,6% patsientidel), kõhukinnisus (3,0%) ja väsimus (1,2%).
English: The figures for day 2 to day 5 were 77% for patients in the Akynzeo group and 70% for those in the palonosetron group.
Estonian: 2. ja 5. päeva näitajad olid Akynzeo rühmas 77% ja palonosetrooni rühmas 70%.
English: What is Akynzeo and what is it used for?
Estonian: Mis on Akynzeo ja milleks seda kasutatakse?
English: Akynzeo is available as capsules containing 300 mg of netupitant and 0.5 mg of palonosetron.
Estonian: Akynzeod turustatakse kapslitena, mis sisaldavad 300 mg netupitanti ja 0,5 mg palonosetrooni.
English: This is a summary of the European public assessment report (EPAR) for Akynzeo.
Estonian: See on ravimi Akynzeo Euroopa avaliku hindamisaruande kokkuvõte.
English: Netupitant works by blocking neurokinin-1 (NK1)
Estonian: Netupitant blokeerib närvisüsteemis leiduvad neurokiniin-1 (NK1) retseptorid, mis
English: receptors, which are found in the nervous system and are responsible for the delayed phase of nausea and vomiting (that occurs after the first 24 hours); palonosetron, on the other hand, blocks 5HT3 receptors in the gut, which are responsible for the immediate phase (that occurs within the first 24 hours).
Estonian: vastutavad iivelduse ja oksendamise hilise faasi eest (tekib esimese 24 tunni järel); palonosetroon blokeerib aga soolestiku 5HT3 retseptorid, mis vastutavad kohese faasi eest (tekib esimese 24 tunni jooksul).
English: This study involved 1,455 patients and the patients took dexamethasone, another medicine used to prevent vomiting, as an additional treatment.
Estonian: Uuringus osales 1455 patsienti ja nad said lisaravina deksametasooni, mis on samuti oksendamist ennetav ravim.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Akynzeo, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Akynzeo omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: In a main study comparing Akynzeo with palonosetron alone, 90% of patients taking Akynzeo (121 out of 135) experienced no vomiting within 5 days of starting highly emetogenic chemotherapy compared with 77% of patients taking palonosetron alone (104 out of 136).
Estonian: Põhiuuringus, milles võrreldi Akynzeod ainult palonosetrooniga, ei oksendanud 5 päeva jooksul pärast tugevalt emetogeense keemiaravi algust 90% Akynzeod võtnud patsientidest (121 patsienti 135st) ja 77% ainult palonosetrooni võtnud patsientidest (104 patsienti 136st).
English: For practical information about using Akynzeo, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Akynzeo kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Akynzeo was effective at preventing both the immediate and delayed phases of nausea and vomiting following chemotherapy, and that the medicine has a favourable safety profile.
Estonian: Inimravimite komitee märkis, et Akynzeo on efektiivne nii keemiaravijärgse iivelduse ja oksendamise kohese kui ka hilise faasi ennetamisel ning et ravimil on soodne ohutusprofiil.
English: Around 88% of patients taking Akynzeo experienced no vomiting on day 1 following the first chemotherapy cycle, compared with 85% of patients taking palonosetron.
Estonian: 1. päeval pärast esimest keemiaravi tsüklit ei oksendanud ligikaudu 88% Akynzeod võtnud patsientidest ja 85% palonosetrooni võtnud patsientidest.
English: A second main study looked at the benefits of Akynzeo in patients undergoing moderately emetogenic chemotherapy.
Estonian: Teises põhiuuringus vaadeldi Akynzeo kasulikkust mõõdukalt emetogeenset keemiaravi saavatel patsientidel.
English: The two active substances in Akynzeo work by blocking two different mechanisms involved in inducing nausea and vomiting during chemotherapy.
Estonian: Akynzeo kaks toimeainet blokeerivad kaks eri mehhanismi, mis põhjustavad keemiaravi ajal iiveldust ja oksendamist.
English: It is not intended to provide practical advice on how to use Akynzeo.
Estonian: Hindamisaruandes ei anta Akynzeo kasutamise praktilisi nõuandeid.
English: How does Akynzeo work?
Estonian: Kuidas Akynzeo toimib?
English: Some chemotherapy is known to induce severe nausea and vomiting, and Akynzeo is used in patients receiving either highly emetogenic (vomit-inducing) chemotherapy based on the cancer medicine cisplatin, or other chemotherapies that are moderately emetogenic.
Estonian: Teadaolevalt põhjustab teatud keemiaravi raskekujulist iiveldust ja oksendamist ning Akynzeod kasutatakse patsientidel, kes saavad kas vähiravimil tsisplatiin põhinevat tugevalt emetogeenset (oksendamist põhjustavat) keemiaravi või muud mõõdukalt emetogeenset keemiaravi.
English: Akynzeo contains the active substances netupitant and palonosetron.
Estonian: Akynzeo sisaldab toimeainetena netupitanti ja palonosetrooni.
English: Akynzeo is a medicine used to prevent nausea (feeling sick) and vomiting in adult patients with cancer who are receiving chemotherapy (medicines to treat cancer).
Estonian: Akynzeo on ravim, mida kasutatakse iivelduse ja oksendamise ennetamiseks täiskasvanud vähipatsientidel, kes saavad keemiaravi (vähiravimid).
English: For more information about treatment with Akynzeo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Akynzeoga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: By having both active substances together, Akynzeo helps provide control for both the immediate and delayed phases of nausea and vomiting than occur following chemotherapy.
Estonian: Tänu mõlemale toimeainele aitab Akynzeo kontrollida pärast keemiaravi tekkiva iivelduse ja oksendamise kohest ja hilist faasi.
English: What are the risks associated with Akynzeo?
Estonian: Mis riskid Akynzeoga kaasnevad?
English: What benefits of Akynzeo have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Akynzeo kasulikkus?
English: The medicine can only be obtained with a prescription.
Estonian: Akynzeo on retseptiravim.
English: How is Akynzeo used?
Estonian: Kuidas Akynzeod kasutatakse?
English: MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administra
Estonian: Tugevus Ravimvorm
English: Adopted at the 8-11 January 2018 PRAC
Estonian: Vastu võetud ravimiohutuse riskihindamise komitee 8.-11. jaanuari 2018 koosolekul
English: Respiratory system
Estonian: Respiratoorne süsteem
English: If you experience symptoms of spitting or coughing up blood you should contact your doctor immediately.
Estonian: Kui teil eritub sülitades või köhides verd, peate võtma kohe ühendust oma arstiga.
English: Patients should be informed of the risk of pneumonitis and advised to contact their doctor immediately should they develop persistent cough or dyspnoea.
Estonian: Patsiente tuleb teavitada pneumoniidi ohust ja soovitada kohe võtta ühendust arstiga, kui tekib püsiv köha või düspnoe.
English: Assessment of respiratory system
Estonian: Respiratoorse süsteemi hindamine
English: Many of the patients in whom these occurred had underlying risk factors for the development of renal events including dehydration or pre-existing hypertension or diabetes.
Estonian: Paljudel patsientidel, kel neid juhte esines, olid eelnevalt neerukahjustuse tekkimise riskifaktorid, nagu dehüdratsioon ja eelnev hüpertensioon või diabeet.
English: Not known: frequency cannot be estimated from the available data Increased urine output
Estonian: Teadmata: esinemissagedust ei saa hinnata olemasolevate andmete alusel Uriinierituse suurenemine
English: Questioning the patient with regard to possible pulmonary dysfunctions, if necessary lung function test.
Estonian: Patsiendi küsitlemine võimaliku kopsufunktsiooni häire suhtes, vajaduse korral kopsufunktsiooni analüüs.
English: The following side effects have also been reported: Frequency not known (cannot be estimated from the available data): bleeding from the lungs
Estonian: Teatatud on ka järgmistest kõrvaltoimetest: Esinemissagedus teadmata (ei saa hinnata olemasolevate andmete alusel): kopsuverejooks
English: Dulaglutide - Gastrointestinal stenosis and obstruction (EPITT no 18931)
Estonian: Dulaglutiid - seedetrakti stenoos ja sulgus (EPITT nr 18931)
English: Acute or chronic interstitial pneumonitis, often associated with blood eosinophilia, may occur and deaths have been reported.
Estonian: Võib tekkida äge või krooniline interstitsiaalne pneumoniit, sageli koos vere eosinofiiliaga, mis on ka surmaga lõppenud.
English: Frequency ‘not known'
Estonian: Esinemissagedus „teadmata“:
English: Bowel obstruction - a severe form of constipation with additional symptoms such as stomach ache, bloating or vomiting
Estonian: Soolesulgus - raske kõhukinnisus koos muude sümptomitega, nagu kõhuvalu, kõhupuhitus või oksendamine
English: Symptoms typically include dyspnoea, cough (especially a dry nonproductive cough), thoracic pain and fever for which patients should be monitored at each follow-up visit.
Estonian: Tüüpiliste sümptomite hulka kuuluvad düspnoe, köha (eriti kuiv, kinnine köha), valu rindkeres ja palavik, mida tuleb kontrollida igal visiidil.
English: Frequency ‘not known': Non-mechanical intestinal obstruction
Estonian: Esinemissagedus „teadmata“: mittemehhaaniline soolesulgus
English: Thirst and increased water consumption Hypernatraemia - increased sodium in blood
Estonian: Hüpernatreemia - vere naatriumisisalduse suurenemine
English: For methotrexate-containing medicinal products with both nononcologic and oncologic indications
Estonian: Metotreksaati sisaldavad ravimpreparaadid nii mitteonkoloogilistel kui ka onkoloogilistel näidustustel
English: Respiratory, thoracic and mediastinal disorders Not known: Epistaxis, Pulmonary alveolar haemorrhage* *(has been reported for methotrexate used in rheumatologic and related indications)
Estonian: Respiratoorsed, rindkere ja mediastiinumi häired Teadmata: epistaksis, kopsualveoolide verejooks* * (on teatatud metotreksaadi kasutamisel reumatoloogilistel ja sarnastel näidustustel)
English: Acute bleeding from the lungs in patients with underlying rheumatologic disease has been reported with methotrexate.
Estonian: Metotreksaadi kasutamisega seoses on reumatoloogilise haigusega patsientidel teatatud ägedast kopsuverejooksust.
English: For methotrexate-containing medicinal products with oncologic indications
Estonian: Metotreksaati sisaldavad ravimpreparaadid onkoloogilistel näidustustel
English: Frequency not known (cannot be estimated from the available data): bleeding from the lungs* *(has been reported for methotrexate used in patients with underlying rheumatologic disease).
Estonian: Teatatud on ka järgmistest kõrvaltoimetest: esinemissagedus teadmata (ei saa hinnata olemasolevate andmete alusel): kopsuverejooks* * (on teatatud metotreksaadi kasutamisel kaasuva reumatoloogilise haigusega patsientidel).
English: If you develop any of the following side effects, contact your doctor immediately: - inflammation of the lungs (symptoms may be general illness, dry, irritating cough, shortness of breath, breathlessness at rest, chest pain, or fever) - spitting or coughing blood
Estonian: − kopsupõletik (sümptomid võivad olla üldine haigestumine, kuiv, ärritav köha, hingeldus, õhupuudus rahuolekus, valu rinnus või palavik)
English: Methotrexate - Pulmonary alveolar haemorrhage (EPITT no 18850)
Estonian: Pemetrekseed - neerutekkene suhkruta diabeet (EPITT nr 18930)
English: For methotrexate-containing medicinal products with non-oncologic indications
Estonian: Metotreksaati sisaldavad ravimpreparaadid mitteonkoloogilistel näidustustel
English: Pemetrexed - Nephrogenic diabetes insipidus (EPITT no
Estonian: Metotreksaat - kopsualveoolide verejooks (EPITT nr
English: Respiratory, thoracic and mediastinal disorders Not known: Epistaxis, Pulmonary alveolar haemorrhage
Estonian: Respiratoorsed, rindkere ja mediastiinumi häired Teadmata: epistaksis, kopsualveoolide verejooks
English: Warnings and precautions
Estonian: Erihoiatused ja ettevaatusabinõud kasutamisel Respiratoorne süsteem
English: MD: entire risk period.
Estonian: MD: kogu riskiperiood.
English: ATCvet code: QI01AD16.
Estonian: ATCvet kood: QI01AD.
English: Do not thaw in hot water or ice cold water.
Estonian: Ärge sulatage kuumas või jääkülmas vees.
English: EU/2/17/213/001-002
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/2/17/213/001-002
English: However, precautionary measures have to be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys.
Estonian: Siiski tuleb järgida ettevaatusabinõusid, et vältida otsest või kaudset kokkupuudet vaktsineeritud kanade ja kalkunite vahel.
English: Safety trials have shown that the strain is safe for turkeys.
Estonian: Ohutusuuringud on näidanud, et tüvi on kalkunitele ohutu.
English: The vaccine is now ready for use.
Estonian: Vaktsiin on nüüd kasutusvalmis.
English: Any person intending to manufacture, import, possess, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Estonian: Iga isik, kes kavatseb toota, importida, omada, müüa, tarnida ja/või kasutada seda veterinaarravimit, peab eelnevalt konsulteerima vastava liikmesriigi vastutava ametkonnaga vaktsineerimispoliitika osas, sest need tegevused võivad olla teatud liikmesriikide territooriumil või osal nende territooriumist siseriiklike õigusaktide kohaselt keelatud
English: Remove the syringe and invert the bag (6-8 times) to mix the vaccine.
Estonian: Eemaldage süstal ja pöörake kotti ümber (6-8 korda) vaktsiini segamiseks.
English: Care should be exercised to prevent contaminating the hands, eyes and clothing with the suspension.
Estonian: Tuleb olla ettevaatlik, et vältida käte, silmade ja riietuse saastamist suspensiooniga.
English: Suspension: off-red to red suspension.
Estonian: Suspensioon: punakas kuni punane suspensioon.
English: MSD Animal Health Logo
Estonian: MSD Animal Healthi logo
English: UNITED STATES OF AMERICA
Estonian: AMEERIKA ÜHENDRIIGID
English: The bag of vaccine should be gently swirled frequently during vaccination to guarantee that the vaccine suspension remains homogenous and that the correct vaccine virus titre is administered (e.g. during long vaccination sessions).
Estonian: Vaktsineerimise ajal tuleb vaktsiinikotti sageli õrnalt keerutada, et tagada vaktsiini suspensiooni jäämine homogeenseks ja vaktsiini õige tiitri manustamine (nt kauakestvate vaktsineerimiste jooksul).
English: If you notice any serious effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Estonian: Kui täheldate tõsiseid kõrvaltoimeid või muid toimeid, mida pole käesolevas pakendi infolehes mainitud, palun teavitage sellest oma veterinaararsti..
English: The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Estonian: Abiained (sealhulgas adjuvandid), mis on loetletud ravimi omaduste kokkuvõtte lõigus 6.1, on kas lubatud ained, millele komisjoni määruse (EL) nr 37/2010 lisa tabelis 1 viidatakse kui ravimjääkide piirnorme mittenõudvatele, või määruse (EÜ) nr 470/2009 reguleerimisalasse mittekuuluvad, kui neid kasutatakse nii nagu selles veterinaarravimis.
English: If frozen suspension is situated in the tip of the ampoule this indicates that the suspension has been thawed and must not be used.
Estonian: Kui külmunud suspensioon paikneb ampulli otsas, tähendab see, et suspensioon on üles sulatatud ja seda ei tohi kasutada.
English: As this is a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys.
Estonian: Kuna tegemist on elusvaktsiiniga, eritub vaktsiini tüvi vaktsineeritud lindudelt ja võib üle kanduda kalkunitele.
English: Preparation of the vaccine:
Estonian: Vaktsiini ettevalmistamine
English: Dry the ampoule, then break the ampoule at its neck and immediately proceed as described below.
Estonian: Kuivatage ampull, seejärel murdke ampull kaelast ja jätkake kohe nii, nagu on kirjeldatud allpool.
English: please note; the sentence ‘for animal treatment only' will only appear in the English and will not be translated
Estonian: Pange tähele, et kokkuleppe kohaselt veterinaarravimite komiteega on lause „for animal treatment only“ inglise keeles ja seda ei tõlgita.
English: It is recommended to handle a maximum of 5 ampoules (from one cane only) at a time.
Estonian: Soovitatav on käsitseda maksimaalselt 5 ampulli (üks varras) korraga.
English: Date of first authorisation: 22/08/2017
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 22.08.2017
English: (number of doses per ampoule is presented on the colour coded clip attached to each cane containing the ampoule)
Estonian: (annuste arv ampulli kohta esitatakse värvikoodiga klambril, mis on kinnitatud iga varda külge, mis sisaldab ampulli)
English: 1 PFU - plaque forming units.
Estonian: 1PFU- naaste moodustav ühik.
English: Suspension: Store and transport frozen in liquid nitrogen (below -140 °C).
Estonian: Suspensioon Hoida ja transportida külmutatult vedelas lämmastikus (alla -140 C).
English: A 3-fold overdose was tested in ovo, which was regarded as safe.
Estonian: In ovo on testitud kolmekordset üleannustamist, see hinnati ohutuks.
English: Preparation of the vaccine shall be planned before the ampoules are taken from the liquid nitrogen and the exact amount of vaccine ampoules and amount of solvent needed shall be calculated first.
Estonian: Vaktsiini valmistamine tuleb planeerida enne ampullide vedelast lämmastikust väljavõtmist ja kõigepealt tuleb arvutada vajalike vaktsiiniampullide ning lahusti täpne kogus.
English: Intervet International B.V. Ambachtstraat 2, 4, 5a 3732 CN De Bilt THE NETHERLANDS
Estonian: Ambachtstraat 2, 4, 5a 3732 CN De Bilt MADALMAAD
English: Innovax-ND-IBD
Estonian: VETERINAARRAVIMI NIMETUS Innovax-ND-IBD
English: Gently swirl and invert the bag to mix the vaccine.
Estonian: Keerutage ja pöörake kotti õrnalt ümber vaktsiini segamiseks.
English: Innovax-ND-IBD is a virus suspension packed in glass ampoules and stored in liquid nitrogen.
Estonian: Innovax-ND-IBD on viiruse suspensioon, mis on pandud klaasampullidesse ja mida säilitatakse vedelas lämmastikus.
English: After removing the ampoule(s), the remaining ampoules should be put back immediately into the canister in the liquid nitrogen container.
Estonian: Pärast ampulli(de) eemaldamist tuleb allesjäänud ampullid panna kohe tagasi vedela lämmastiku mahutis olevasse kanistrisse.
English: Suspension: - One Type I glass ampoule of 2 ml containing 2,000 or 4,000 doses.
Estonian: Suspensioon: - I tüüpi klaasist ampull, mis sisaldab 2000 või 4000 annust.
English: The handling of liquid nitrogen should take place in a well-ventilated area.
Estonian: Vedela lämmastiku käsitsemine peab toimuma hästi ventileeritavas kohas.
English: Control of correct storage:
Estonian: Õige säilitamise kontroll